Ann: Veyonda and Radiotherapy Delivers Clinical Benefits, page-14

Who would have every thought the palliative radiotherapy would not provide pain relief and tumor responses. https://www.bmj.com/content/360/bmj.k821

"Palliative radiotherapy remains the gold standard treatment for painful bone metastases in all cancers including prostate cancer."  BMJ 2018 23 march.   
https://www.bmj.com/content/360/bmj.k821/rapid-responses

Again and again  the results are the same as what idronoxil has always predicted or even without idronoxil.
30 % reduction in pain is great for the patients, I agree but to read into that some sort validation of the drug is simply a guess work at best.   There is not a scrap of evidence to say that it is anything other than what can be predicted by palliative care.

Note the results in "Percentage change in prostate specific antigen, from baseline to 12-weeks, by patient".
and the admision that 400mg dose has not medical effect

"400 mg cohort, this dose did not appear to have any significant anti-cancer effect in this small number of patients."

Yet all blue patients achieved SD and on the better half of the chart but attributed to what then???????   And most importantly match the patient numbers to the results.   

Considering RBX was forecasting these results to be out by last Aug, due to the speed and simplicity of the treatment, considering the use of the word abscopal was been bandied around with any sense of caution and considering investors stumped up 10 M at 90 cents it is easy to understand the disappointment with today's data. People were expecting a disruptive technology, because that was the wording used. What we have seen so far with CEP1 and today's results is the same old same response idronoxil has always delivered. It may find some market value at the end, but it is certainly not the blockbuster being touted management.

I thought it pretty poor form to have Greg carry the news today and his body language said it all.